Table 3.
Cellular alternation in peripheral blood leucocytes profile of EAC mice treated with Cisplatin®, p. pavonica and J. ruben extracts
| Treatments | WBC count (× 03) | Leucocytes differentials relative number (%) | |||
|---|---|---|---|---|---|
| Lymphocytes | Neutrophils | Monocytes | |||
| P. pavonica | Low dose | 11.96 ± 0.60a | 77.00 ± 7.93 | 4.66 ± 0.08 | 24.33 ± 3.05 |
| High dose | 2.35 ± 0.50 | 76.00 ± 3.60 | 2.00 ± 0.05a | 21.33 ± 2.52 | |
| Prophylactic dose | 5.36 ± 0.66 | 76.33 ± 6.42 | 4.33 ± 0.09 | 18.66 ± 2.23 | |
| J. rubens | Low dose | 6.46 ± 0.30 | 86.00 ± 5.30 | 1.66 ± 0.04a | 12.00 ± 3.29 |
| High dose | 3.63 ± 0.93 | 78.00 ± 6.00 | 4.00 ± 0.09a | 17.33 ± 4.32 | |
| Prophylactic dose | 9.23 ± 1.40ab | 76.66 ± 8.50 | 1.66 ± 0.02a | 21.66 ± 1.02 | |
| EAC + PBS | 5.20 ± 0.70 | 72.66 ± 9.72 | 7.66 ± 0.06 | 23.66 ± 3.06 | |
| EAC + Cisplatin® | 6.46 ± 0.50 | 70.00 ± 7.64 | 1.33 ± 0.08 | 25.33 ± 2.50 | |
Data were represented as mean ± SD
The difference between groups was considered statistically significant at P < 0.05. a: statistically significant vs. EAC mice. b: statistically significant vs. EAC mic + Cisplatin®